Efficacy of Tadalafil Therapy and Changes in Oxidative Stress Levels in Male Patients with Lower Urinary Tract Symptoms and Overactive Bladder.
lower urinary tract symptoms
overactive bladder
oxidative stress
tadalafil
urodynamic parameters
Journal
Lower urinary tract symptoms
ISSN: 1757-5672
Titre abrégé: Low Urin Tract Symptoms
Pays: Australia
ID NLM: 101506777
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
23
01
2019
revised:
30
04
2019
accepted:
22
07
2019
pubmed:
14
8
2019
medline:
15
12
2020
entrez:
14
8
2019
Statut:
ppublish
Résumé
To evaluate the effects of tadalafil monotherapy on lower urinary tract symptoms, urodynamic parameters, and oxidative stress levels in male patients. This prospective study included 53 male patients with urinary symptoms, who met the criteria for overactive bladder (OAB) (≥ 2 points for Q3 [urgency] in the OAB symptom score [OABSS] assessment and ≥ 3 points for the total score). The patients received 5 mg tadalafil orally once daily, and their symptoms were assessed before and after the 12-week treatment. The OABSS and international prostate symptom score (IPSS) were used to evaluate the subjective symptoms. The objective findings were assessed using uroflowmetry. Oxidative stress was assessed by determining urinary levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels with an adjustment for urinary creatinine (CR) concentration. After tadalafil administration, total and individual indices of the OABSS assessment showed significant improvement. In addition, total storage and voiding symptoms that contributed to the IPSS were also significantly improved. The voided volume was increased, and the maximum flow rate was improved after tadalafil treatment (P = .002 and < 0.001, respectively). Urinary 8-OHdG/CR decreased from 12.4 ± 9.7 ng/mg CR to 7.6 ± 11.6 ng/mg CR (P < .001). In patients who showed OAB improvement and did not meet the criteria for OAB after the treatment (44 patients, 83.0%), the urinary 8-OHdG/CR level was significantly decreased from 11.6 ± 8.4 ng/mg CR to 6.4 ± 10.3 ng/mg CR (P < .001). Tadalafil treatment improves OAB symptoms and urodynamic parameters by decreasing oxidative stress level.
Identifiants
pubmed: 31407871
doi: 10.1111/luts.12283
pmc: PMC7004155
doi:
Substances chimiques
Urological Agents
0
Tadalafil
742SXX0ICT
8-Hydroxy-2'-Deoxyguanosine
88847-89-6
Types de publication
Controlled Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
47-53Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 The Authors. LUTS: Lower Urinary Tract Symptoms published by John Wiley & Sons Australia, Ltd.
Références
Low Urin Tract Symptoms. 2020 Jan;12(1):47-53
pubmed: 31407871
Environ Int. 2019 Feb;123:301-309
pubmed: 30553203
Curr Opin Urol. 2010 Jan;20(1):49-54
pubmed: 19887943
Phytother Res. 2010 Feb;24(2):301-3
pubmed: 19585469
BJU Int. 2013 Nov;112(7):990-7
pubmed: 23937669
World J Urol. 2008 Dec;26(6):603-9
pubmed: 18607596
Int J Urol. 2012 Jul;19(7):669-75
pubmed: 22458726
J Urol. 2013 Jan;189(1 Suppl):S135-40
pubmed: 23234619
Asian J Androl. 2012 Jul;14(4):616-20
pubmed: 22504870
J Sex Med. 2011 Oct;8(10):2746-60
pubmed: 21812935
Eur Urol. 2011 Nov;60(5):1105-13
pubmed: 21871706
Med Oncol. 2017 Apr;34(4):57
pubmed: 28281193
Dis Markers. 2018 May 2;2018:7916578
pubmed: 29854026
BJU Int. 2019 May;123(5):877-884
pubmed: 30216623
Neurourol Urodyn. 2018 Feb;37(2):666-672
pubmed: 28782191
Res Rep Urol. 2017 Jun 10;9:93-100
pubmed: 28652996
Neurourol Urodyn. 2017 Aug;36(6):1488-1495
pubmed: 27701772
BJU Int. 2012 Sep;110(6 Pt B):E259-66
pubmed: 22591258
J Urol. 1999 Nov;162(5):1768-78
pubmed: 10524933
Neurourol Urodyn. 2012 Jan;31(1):195-200
pubmed: 21905085
Low Urin Tract Symptoms. 2019 Apr;11(2):O193-O201
pubmed: 29282885
Prostate. 2002 Apr 1;51(1):50-8
pubmed: 11920958
BJU Int. 2012 Sep;110(6 Pt B):E236-44
pubmed: 22639915
Andrologia. 2018 Oct;50(8):e13068
pubmed: 29917246
Free Radic Biol Med. 2013 Jul;60:80-8
pubmed: 23385031
Int J Urol. 2018 Mar;25(3):246-250
pubmed: 29164680
Aging Cell. 2014 Jun;13(3):540-50
pubmed: 24593692
BJU Int. 2010 Feb;105(4):502-7
pubmed: 19732051